Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Osteoporosis: underrated, underdiagnosed and undertreated.

Tuan V Nguyen1, Jacqueline R Center, John A Eisman

  • 1Bone and Mineral Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

The Medical Journal of Australia
|February 27, 2004
PubMed
Summary

Osteoporosis is an underrated, underdiagnosed, and undertreated condition in Australia, costing billions annually. Early investigation and effective treatments are crucial for reducing fracture risk and improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.

Nature genetics·2026
Same author

Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.

bioRxiv : the preprint server for biology·2026
Same author

Bone health in adults with non-ambulatory neuromuscular disorders: scoping review of risk factors, diagnosis and management.

Internal medicine journal·2026
Same author

Protocol summary and statistical analysis plan for the bone loss prevention with zoledronic acid or denosumab in critically ill adults (BONE ZONE) trial.

Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine·2026
Same author

Correction: Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Correction: A meta-analysis of previous falls and subsequent fracture risk in cohort studies.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026

Area of Science:

  • Gerontology
  • Public Health
  • Endocrinology

Background:

  • Osteoporosis poses a significant health and economic burden, with high morbidity and mortality rates following fractures.
  • Genetic, lifestyle, and hormonal factors contribute to osteoporosis risk.
  • Low bone density is a strong predictor of future fracture risk.

Purpose of the Study:

  • To highlight the underrated, underdiagnosed, and undertreated nature of osteoporosis.
  • To emphasize the importance of investigating low-trauma fractures for osteoporosis.
  • To advocate for increased screening and effective treatment of osteoporosis.

Main Methods:

  • Review of current statistics on osteoporosis costs and prevalence in Australia.
  • Analysis of diagnostic criteria and predictors of fracture risk.

Related Experiment Videos

  • Evaluation of the efficacy of existing osteoporosis treatments and preventative measures.

    • Main Results:

    • Osteoporosis costs Australia approximately $7 billion annually.
    • Over 75% of women and 90% of men at high risk are not investigated for osteoporosis.
    • More than 75% of affected individuals remain untreated despite effective therapies.

    Conclusions:

    • Osteoporosis is significantly underrated, underdiagnosed, and undertreated, necessitating urgent public health attention.
    • Investigating all low-trauma fractures for osteoporosis and initiating prompt treatment can significantly reduce future fracture risk.
    • Effective treatments, including hormone replacement therapy, selective oestrogen receptor modifiers, bisphosphonates, and lifestyle interventions, can decrease fracture risk by 30%-60%.